News and Announcements
First Two Patients in Clinical Trial for Canine Cancer Begin Treatment
- Published October 23, 2014 9:36AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX Release – Wednesday 22nd October 2014
PharmAust Limited (ASX:PAA & PAAO) is pleased to announce that it has now initiated its trial of PPL-1 in dogs for the treatment of canine cancers. Within the last week, two dogs have begun treatment with PPL-1 formulated in “soft-gel” capsules to determine the safety and efficacy of PPL-1 in various canine cancers.
Dr Angela Frim berger of the Animal Referral Hospital (ARH) in Homebuss, NSW and Principal Investigator in the trial said,” The palatability issues of PPL-1 in dogs have largely been resolved by reformulation of PPL-1 into a tasteless, soft gel capsule making administration to pets by their owners far more practicable. Following our call for accrual of canine patients, we are seeing good progress in patient recruitment.”
To view the full ASX release, please click here.